ArticleCancer management and research2026
Development and Internal Validation of a Nomogram for Predicting Recurrence in Endometrial Cancer Based on Pathological and Histological Indicators.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial cancer (EC) is a common malignant tumor in the female reproductive system. Identifying patients with a high risk of recurrence is beneficial for formulating personalized follow-up and treatment plans. This study aims to develop a prediction model for evaluating the risk of recurrence of EC after treatment. Methods: This study conducted a retrospective analysis on 486 patients with EC and randomly divided them into a training group (n = 389) and a validation group (n = 97). A nomogram was constructed after identifying predictors. The concordance index (C-index), receiver operating characteristic (ROC) curve, calibration plots, net reclassification index (NRI), integrated discrimination improvement (IDI), decision curve analysis (DCA) and Kaplan-Meier curves were used to evaluate the predictive model for EC recurrence. Results: A predictive nomogram was constructed based on the six selected predictors. The ROC curve (area under the curve = 0.890) and calibration curve indicate that the model has high discrimination and calibration capabilities. The NRI in the training set was 0.321 (95% CI: 0.031-0.438), and the IDI was 0.133 (95% CI: 0.052-0.215), indicating a significant improvement compared to the ESGO-ESTRO-ESP pattern. The DCA curves indicated that this model exhibited excellent discriminative performance and clinical application value. Conclusion: A nomogram based on pathological factors and immunohistochemical indicators was constructed and validated for predicting the recurrence of EC. Its predictive performance was superior to the ESGO-ESTRO-ESP pattern, and it can be used as a prognostic tool for clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.